In a recent retrospective database study of outcomes at US community oncology practices of 7746 patients initiating first-line therapy (March 2015–August 2018) for advanced NSCLC with no documented EGFR/ALK genomic alterations, 907 patients who initiated first-line ICI monotherapy experienced median OS of 19.9 months (95% CI, 16.6–24.1), superior to median OS with other recorded therapies (9). The gene discussed is ALK; the disease is non-small cell lung carcinoma.